Paul Tesha

Papers

1

Total Citations

12

H-Index

1

About

Dr. Paul Tesha is a leading clinical researcher in ophthalmology, with a primary focus on neovascular age-related macular degeneration (nAMD), a leading cause of blindness worldwide. His most impactful work centers on the development of stereotactic radiotherapy as a novel, non-invasive treatment for this condition. Dr. Tesha served as a key investigator on the landmark STAR trial, a pivotal, randomized, double-masked, sham-controlled device study published in 2024. This major contribution demonstrated that targeted radiation can effectively reduce the treatment burden of frequent anti-VEGF injections for nAMD patients. With 12 citations already, the STAR trial is rapidly shaping clinical practice by offering a durable, one-time alternative to lifelong injections. Dr. Tesha’s work bridges the gap between radiation oncology and retinal disease, providing a paradigm shift in managing chronic eye disease. His research is essential reading for students and clinicians interested in innovative, device-based therapies that improve patient quality of life and reduce healthcare costs.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
12 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 46

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago